Elevated profiles of peripheral Th22, Th17, Th2 cells, and decreased percentage of Th1 cells in breast cancer patients
ConclusionTh22, Th17, Th1, and Th2 subsets may play an essential role in BC patients. Th22, Th17, Th1, and Th2 cells may have potential significance to be used as clinical markers in BC patients with different molecular classification. Th22 cells may have potential value in BC patients ’ outcomes prediction, providing clinical value. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Zhiguo Peng,
Xinyue Dong,
Miao He,
Yajing Zhao,
Yujia Liu,
Mo Li,
Guosheng Li,
Xiuwen Wang,
Li Li,
Yu Hu Tags: ORIGINAL ARTICLE Source Type: research
Intrinsic resistance to ROS1 inhibition in a patient with CD74 ‐ROS1 mediated by AXL overexpression
ConclusionsIn summary, we demonstrate that AXL overexpression is a mechanism of intrinsic resistance to ROS1 inhibitors. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 20, 2023 Category: Cancer & Oncology Authors: Tara L. Peters,
Nan Chen,
Logan C. Tyler,
Anh T. Le,
Anastasios Dimou,
Robert C. Doebele Tags: ORIGINAL ARTICLE Source Type: research
Extracellular shuttling miR ‐21 contributes to esophageal cancers and human umbilical vein endothelial cell communication in the tumor microenvironment and promotes tumor angiogenesis by targeting phosphatase and tensinhomolog
ConclusionExo-miR-21-mediated communication between endothelial and cancer cells plays a pivotal role in promoting the angiogenesis of ESCC. Therefore, controlling exo-miR-21 could serve as a novel therapeutic strategy for ESCC by targeting angiogenesis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 20, 2023 Category: Cancer & Oncology Authors: Shanbo Zheng,
Juan Liao,
Mingjun Sun,
Ran Liu,
Junjie Lv Tags: ORIGINAL ARTICLE Source Type: research
Prognostic and predictive impact of molecular tumor burden index in non ‐small cell lung cancer patients
ConclusionΔmTBI had a good sensitivity to identify potential beneficial patients based on the best effect CT scans, demonstrating that mTBI dynamics were predictive of benefit from immune checkpoint blockade. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Fan Yang,
Min Tang,
Liang Cui,
Jing Bai,
Jiangyong Yu,
Jiayi Gao,
Xin Nie,
Xu Li,
Xuefeng Xia,
Xin Yi,
Ping Zhang,
Lin Li Tags: ORIGINAL ARTICLE Source Type: research
Expert consensus on the diagnosis and treatment of RET gene fusion non ‐small cell lung cancer in China
Diagnosis and treatment process of RET gene fusion non-small cell lung cancer in China. AbstractThe rearranged during transfection (RET) gene is one of the receptor tyrosine kinases and cell-surface molecules responsible for transmitting signals that regulate cell growth and differentiation. In non-small cell lung cancer (NSCLC), RET fusion is a rare driver gene alteration associated with a poor prognosis. Fortunately, two selective RET inhibitors (sRETi), namely pralsetinib and selpercatinib, have been approved for treating RET fusion NSCLC due to their remarkable efficacy and safety profiles. These inhibitors have shown ...
Source: Thoracic Cancer - September 18, 2023 Category: Cancer & Oncology Authors: Xingxiang Pu,
Chunwei Xu,
Qian Wang,
Wenxian Wang,
Fang Wu,
Xiuyu Cai,
Zhengbo Song,
Jinpu Yu,
Wenzhao Zhong,
Zhijie Wang,
Yongchang Zhang,
Jingjing Liu,
Shirong Zhang,
Anwen Liu,
Wen Li,
Ping Zhan,
Hongbing Liu,
Tangfeng Lv,
Liyun Miao, Tags: CLINICAL GUIDELINE Source Type: research
Altered functional connectivity of the nucleus tractus solitarii in patients with chronic cough after lung surgery: an rs ‐fMRI study
ConclusionsReduced FC of the NTS with ACC may be associated with cough hypersensitivity and may contribute to anxiety in patients with chronic cough after lung surgery. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 18, 2023 Category: Cancer & Oncology Authors: Ming ‐sheng Wu,
Zheng‐wei Chen,
Xiao Chen,
Gao‐xiang Wang,
Chun‐sheng Xu,
Yong‐fu Zhu,
Ming‐ran Xie Tags: ORIGINAL ARTICLE Source Type: research
Molecular mechanism underlying epithelial ‐mesenchymal transformation and cisplatin resistance in esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC) frequently develops resistance to cisplatin chemotherapy, a challenge linked to the epithelial-mesenchymal transformation (EMT) process. Our review elucidates the molecular crosstalk between EMT and cisplatin resistance in ESCC, spotlighting signaling pathways such as FOXO1, PI3K/Akt, and Wnt. Our insights offer a foundation for innovative therapeutic interventions, potentially revolutionizing ESCC treatment. AbstractEsophageal cancer (EC) occupies the seventh spot of the most prevalent malignancy cancer ailments worldwide and the sixth leading cause of cancer-related death. Esopha...
Source: Thoracic Cancer - September 18, 2023 Category: Cancer & Oncology Authors: Kewei Song,
Chenhui Ma,
Baohong Gu,
Bofang Wang,
Huanhuan Ma,
Xiaobo Deng,
Hao Chen Tags: REVIEW Source Type: research
Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy
ConclusionBevacizumab significantly reduces the severity of PTBE after radiotherapy for lung cancer. However, its impact on tumor volume reduction and intracranial PFS does not reach statistical significance. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 18, 2023 Category: Cancer & Oncology Authors: Yi ‐Chun Hua,
De‐Zhi Gao,
Kuan‐Yu Wang,
Xiao‐Sheng Ding,
Wei‐Ran Xu,
Yu‐Bin Li,
Wei‐Wei Shi,
Shi‐Bin Sun,
Xiao‐Yan Li Tags: ORIGINAL ARTICLE Source Type: research
A multicenter, open ‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer
ConclusionCombination chemotherapy with PEM plus Bev in elderly patients with previously untreated advanced non-squamous NSCLC exhibited favorable antitumor activity and tolerability, suggesting that a combination of PEM plus Bev might be a promising treatment option for this population. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 18, 2023 Category: Cancer & Oncology Authors: Yohei Yabuki,
Masaki Hanibuchi,
Eiji Takeuchi,
Takashi Haku,
Takanori Kanematsu,
Naoki Nishimura,
Yuko Toyoda,
Atsushi Mitsuhashi,
Kenji Otsuka,
Seidai Sato,
Hisatsugu Goto,
Hiroto Yoneda,
Hirokazu Ogino,
Hiroshi Nokihara,
Shinohara Tsutomu, Tags: ORIGINAL ARTICLE Source Type: research
Bronchoscopy for management and identification of etiology of right middle lobe syndrome: Analysis of 66 cases
ConclusionsMalignancy was identified as the etiology of RML syndrome in approximately 25% of cases, suggesting bronchoscopy should be performed in every case of RML atelectasis. To our knowledge, this is the first reported series of endobronchial stenting of the RML bronchus in the context of RML syndrome. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 14, 2023 Category: Cancer & Oncology Authors: Lev Freidkin,
Moshe Heching,
Dror Rosengarten,
Barak Pertzov,
Evgeni Gershman,
Shimon Izhakian,
Shai M. Amor,
Mordechai Reuven Kramer Tags: ORIGINAL ARTICLE Source Type: research
Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first ‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study
ConclusionsOur study revealed potential differences in TKI efficacy, resistance mechanism, and prognosis of various EGFR ex19del subtypes in NSCLC, underscoring the need for precise selection of first-line therapy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 14, 2023 Category: Cancer & Oncology Authors: Yangchun Gu,
Jinyu Yu,
Haifeng Hu,
Hua Zhang,
Baoshan Cao,
Li Liang Tags: ORIGINAL ARTICLE Source Type: research
Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
ConclusionsDeleterious mutations of these six genes were common in resected NSCLC and could serve as prognostic biomarkers. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 14, 2023 Category: Cancer & Oncology Authors: Haoran Zhang,
Dongming Zhang,
Jia Liu,
Yuequan Shi,
Xiaoyan Liu,
Minjiang Chen,
Wei Zhong,
Jing Zhao,
Yan Xu,
Mengzhao Wang Tags: ORIGINAL ARTICLE Source Type: research
Survival outcomes of east Asian patients with advanced non ‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence
ConclusionsThis real-world evidence shows that afatinib confers better survival than other first-line EGFR-TKIs in East Asian patients with advanced NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 14, 2023 Category: Cancer & Oncology Authors: Huang ‐Chih Chang,
Kuo‐Tung Huang,
Chia‐Cheng Tseng,
Yu‐Mu Chen,
Chien‐Hao Lai,
Yu‐Ping Chang,
Yung‐Che Chen,
Hung‐Yi Chuang,
Chin‐Chou Wang Tags: ORIGINAL ARTICLE Source Type: research
Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report
We present a unique case of hyperprogressive disease (HPD) of lung cancer. The patient rapidly developed multiple lung metastases without target-lesion progression 3 weeks after the introduction of durvalumab following curative chemoradiotherapy for postoperative mediastinal lymph node recurrence of lung cancer. HPD may be suspected when multiple metastases appear in the new organs early after the administration of immune-checkpoint inhibitors. AbstractHyperprogressive disease (HPD) is a novel progressive pattern that occurs after immune checkpoint inhibitor (ICI) administration. Here, a 74-year-old woman who had underg...
Source: Thoracic Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Kosuke Masuda,
Yoshiaki Nagai,
Hikari Amari,
Hiroki Tahara,
Yuki Maeda,
Jun Shiihara,
Hiromitsu Ohta,
Masahiro Hiruta,
Yasuhiro Yamaguchi Tags: CASE REPORT Source Type: research
Nivolumab as maintenance therapy following platinum ‐based chemotherapy in EGFR‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial
ConclusionNivolumab maintenance following platinum-based chemotherapy did not show clinical benefits after EGFR-TKI failure in patients withEGFR-mutant NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Jiwon Kim,
Chang ‐Min Choi,
Wonjun Ji,
Jae Cheol Lee Tags: ORIGINAL ARTICLE Source Type: research
